Envista (NYSE:NVST) Price Target Cut to $23.00

Envista (NYSE:NVST) had its price objective lowered by research analysts at JPMorgan Chase & Co. from $29.00 to $23.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 16.34% from the company’s current price.

A number of other brokerages have also recently issued reports on NVST. Morgan Stanley cut Envista from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $33.00 to $21.00 in a report on Friday, April 26th. Leerink Partnrs reissued an “underperform” rating on shares of Envista in a research report on Monday, February 26th. TheStreet lowered shares of Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. UBS Group started coverage on Envista in a report on Friday, January 5th. They issued a “neutral” rating and a $26.00 price target for the company. Finally, William Blair cut Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $26.27.

Envista Trading Up 0.1 %

Shares of NVST traded up $0.02 during mid-day trading on Thursday, hitting $19.77. The company had a trading volume of 2,134,817 shares, compared to its average volume of 2,298,014. Envista has a 1-year low of $18.09 and a 1-year high of $38.42. The business’s 50-day simple moving average is $20.80 and its 200-day simple moving average is $22.59. The stock has a market cap of $3.40 billion, a PE ratio of -32.66, a P/E/G ratio of 3.72 and a beta of 1.35. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The firm had revenue of $623.60 million for the quarter, compared to analyst estimates of $634.85 million. During the same quarter in the previous year, the company earned $0.38 earnings per share. The company’s quarterly revenue was down .6% on a year-over-year basis. Sell-side analysts forecast that Envista will post 1.41 earnings per share for the current year.

Institutional Trading of Envista

Several institutional investors have recently added to or reduced their stakes in the stock. Headinvest LLC acquired a new stake in Envista during the third quarter valued at approximately $28,000. Fifth Third Bancorp raised its position in shares of Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after acquiring an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in Envista during the third quarter worth $47,000. Signaturefd LLC boosted its holdings in Envista by 1,297.9% in the fourth quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock worth $63,000 after purchasing an additional 2,427 shares during the period. Finally, Covestor Ltd increased its stake in Envista by 33.9% during the third quarter. Covestor Ltd now owns 2,462 shares of the company’s stock valued at $69,000 after purchasing an additional 624 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.